DOE Milestone on Aurora-INL
On June 11, 2026, the DOE approved the Preliminary Documented Safety Analysis for the Aurora powerhouse at INL, a critical step in the regulatory pathway toward construction and operation.
Source: 10-Q Item 2 MD&A
Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
OKLO's Q2 FY2026 filing marks the company's first revenue from recently acquired engineering subsidiaries, while operating losses more than doubled year-over-year as R&D spending ramped up for regulatory and deployment milestones. Management highlighted DOE approval of the Preliminary Documented Safety Analysis for the Aurora powerhouse and the startup authorization for the Groves Isotope Test Reactor as key de-risking events. The company's cash position remains exceptionally strong following financing activities, but cash burn from operations and investments accelerated, underscoring the capital-intensive nature of its build-own-operate model. The path to its first powerhouse deployment in 2028 remains dependent on continued regulatory progress and supply chain execution.
EPS (Diluted)
-$0.28
-55.56% YoY
Operating Income
-$73.19M
-161.25% YoY
Source: SEC XBRL
OKLO's fiscal Q2 FY2026 corresponds to calendar Q2 2026.
Last 4 quarters: 1 beat
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026This filing | -0.28 | -0.16 | Miss -70.6% |
| Mar 2026 | -0.19 | -0.20 | Beat +3.4% |
| Dec 2025 | -0.27 | -0.17 | Miss -56.2% |
| Sep 2025 | -0.20 | -0.13 | Miss -49.4% |
Reported EPS of -$0.28 versus the -$0.16 analyst consensus — a -70.6% miss for Jun 2026.
Compiled by AI from 10-Q Item 2 of this filing
On June 11, 2026, the DOE approved the Preliminary Documented Safety Analysis for the Aurora powerhouse at INL, a critical step in the regulatory pathway toward construction and operation.
Source: 10-Q Item 2 MD&A
Oklo entered into a prepayment agreement with Meta Platforms to develop a 1.2 GW power campus in Ohio, providing a mechanism for Meta to prepay for power and fund powerhouse deployment.
Source: 10-Q Item 2 MD&A
Oklo generated its first revenue of $1.21 million in the six months ended June 30, 2026, from acquired engineering subsidiaries ARMEC and Creative Engineers, which provide advanced nuclear engineering services.
Source: 10-Q Item 2 MD&A
After the quarter end, the DOE granted startup authorization for the Groves Isotope Test Reactor, and it achieved first criticality on August 5, 2026, demonstrating Oklo's reactor design and operational capabilities.
Source: 10-Q Item 2 MD&A
Oklo expects 2026 operating cash outflow of $120M–$150M and capital expenditures of $400M–$500M, reflecting heavy investment in facility deployment and regulatory activities.
Source: 10-Q Item 2 MD&A
Compiled by AI from this SEC filing · 3 high, 2 medium, 0 low
Operating cash outflow was $65.5M and investing cash outflow was $912.7M in the first half of FY2026, far exceeding the $1.21M in revenue, indicating a rapid cash consumption that could strain resources if financing is not repeated.
Source: 10-Q Cash Flow Statement (XBRL)
Revenue of $1.21M is solely from acquired engineering services, not from the core power sales business; the build-own-operate model has yet to generate its first power sale, making future revenue projections highly speculative.
Source: 10-Q Income Statement (XBRL)
Net loss widened 96.6% year-over-year to $48.5M, resulting in negative ROE of –1.48% and ROA of –1.45%, highlighting the company's yet-unproven path to profitability.
Source: 10-Q Income Statement (XBRL)
Cash and equivalents make up 49% of total assets, reflecting reliance on financing proceeds; if deployment milestones are delayed, these funds may be consumed without generating returns.
Source: 10-Q Balance Sheet (XBRL)
Financing activities provided $1.85B in the first half of FY2026, which is critical to funding operations and investments; any disruption in capital markets or investor sentiment could jeopardize the company's ambitious spending plans.
Source: 10-Q Cash Flow Statement (XBRL)
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $MYTD | 1.21 $M | 0.00 $M | — |
Operating Income $M | -73.19 $M | -28.02 $M | -161.25% |
Net Income $M | -48.54 $M | -24.69 $M | -96.62% |
EPS (Basic) $ | -0.28 $ | -0.18 $ | -55.56% |
EPS (Diluted) $ | -0.28 $ | -0.18 $ | -55.56% |
R&D Expense $M | 39.47 $M | 11.47 $M | +244.21% |
Answers draw on this SEC filing and the data on this page
Expected release date, analyst estimates & what to watch
Oklo reported a dramatically widened net loss of -$33.1M in Q1 2026 (vs. -$9.8M a year ago) driven by a 244.7% surge in R&D spending, while its balance sheet expanded nearly 8x to $2.7B in total assets following a major financing event that raised over $1.18B in cash.
Oklo reported a dramatically widened operating loss of -$139.3M in FY2025 (vs. -$52.8M prior year) as R&D spending more than doubled, while a major equity raise boosted cash to $788.4M and stockholders' equity to $1.48B, positioning the pre-revenue company for its advanced fission reactor development program.